candesartan has been researched along with Cirrhosis in 40 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hypertensive patients (n = 196) with echocardigraphically documented left ventricular hypertrophy were randomized to candesartan 8-16 mg/day (n = 91) or enalapril 10-20 mg/day (n = 105) with possible addition of hydrochlorothiazide (12." | 9.14 | Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angiotensin-co ( Ciulla, MM; Cuspidi, C; Esposito, A; Magrini, F; Muiesan, ML; Paliotti, R; Rosei, EA; Zanchetti, A, 2009) |
| "Withaferin A protects against the CKD progression that is, at least in part, associated with the moderation of ER stress-related apoptosis, inflammation, and fibrosis in the kidneys of CKD." | 7.96 | Withaferin A protects against endoplasmic reticulum stress-associated apoptosis, inflammation, and fibrosis in the kidney of a mouse model of unilateral ureteral obstruction. ( Chen, CM; Chiang, CK; Chung, YP; Guan, SS; Huang, KT; Liu, CH; Liu, SH; Wu, CT, 2020) |
| "To examine the additive protective effects of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone (Pio) and the angiotensin II receptor blocker candesartan (Cand) in a murine model of renal fibrosis: mice with unilateral ureteral obstruction (UUO)." | 7.76 | Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice. ( Higashi, K; Hyodo, T; Kumagai, H; Kushiyama, T; Miura, S; Oda, T; Sakurai, Y; Suzuki, S; Yamada, M, 2010) |
| "Rabbits subjected to ventricular tachypacing at 380 to 400 bpm for 4 weeks in the absence and presence of treatment with pioglitazone, candesartan, and combined pioglitazone and candesartan were assessed by electrophysiologic study, atrial fibrosis measurements, and cytokine expression analyses." | 7.74 | Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. ( Harata, S; Inden, Y; Kitamura, K; Murohara, T; Nattel, S; Shimano, M; Tsuji, Y; Uchikawa, T, 2008) |
| "We recently demonstrated that both lisinopril and candesartan, an angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor blocker, respectively, attenuate pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori (WBN/Kob) rats." | 7.73 | Combination therapy with an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker synergistically suppresses chronic pancreatitis in rats. ( Ando, T; Itoh, M; Joh, T; Kuno, A; Masuda, K; Nakamura, S; Nomura, T; Ogawa, K; Ohara, H; Okamoto, T; Shirai, T; Tang, M; Yamada, T, 2005) |
| "The goal of this study was to determine whether an Angiotensin II receptor antagonist, candesartan, prevents myocardial fibrosis more effectively than enalapril in animals with a non-ACE pathway during the progression of congestive heart failure (CHF)." | 7.72 | Candesartan prevents myocardial fibrosis during progression of congestive heart failure. ( Dohi, K; Funabiki, K; Imanaka-Yoshida, K; Ito, M; Kitamura, T; Koji, T; Nakano, T; Nobori, T; Onishi, K, 2004) |
| "Candesartan treatment also increased the amount of fecal short-chain fatty acids (SCFAs) including acetic acid, propionic acid, and butyric acid in SHRs." | 5.51 | Candesartan attenuates hypertension-associated pathophysiological alterations in the gut. ( Chen, Y; Cui, J; Ding, L; Du, X; Tang, X; Wang, P; Wang, W; Wu, D; Yin, J; Zhang, T, 2019) |
| " Chronic administration of a subdepressor dose of an angiotensin II type 1 receptor blocker candesartan reduced the pressure overload-induced dihydroethidium and 4-HNE signals at day 3." | 5.33 | Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II. ( Fukui, D; Imaizumi, T; Kai, H; Kudo, H; Kuwahara, F; Mori, T; Sugi, Y; Tahara, N; Takayama, N; Takemiya, K; Tokuda, K; Yasukawa, H, 2006) |
| "Hypertensive patients (n = 196) with echocardigraphically documented left ventricular hypertrophy were randomized to candesartan 8-16 mg/day (n = 91) or enalapril 10-20 mg/day (n = 105) with possible addition of hydrochlorothiazide (12." | 5.14 | Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angiotensin-co ( Ciulla, MM; Cuspidi, C; Esposito, A; Magrini, F; Muiesan, ML; Paliotti, R; Rosei, EA; Zanchetti, A, 2009) |
| "Withaferin A protects against the CKD progression that is, at least in part, associated with the moderation of ER stress-related apoptosis, inflammation, and fibrosis in the kidneys of CKD." | 3.96 | Withaferin A protects against endoplasmic reticulum stress-associated apoptosis, inflammation, and fibrosis in the kidney of a mouse model of unilateral ureteral obstruction. ( Chen, CM; Chiang, CK; Chung, YP; Guan, SS; Huang, KT; Liu, CH; Liu, SH; Wu, CT, 2020) |
| " Although both tempol and candesartan effectively reduced reactive oxygen species production in the kidney, tempol did not decrease blood pressure and exacerbated urine protein and histological damage, such as glomerulosclerosis and interstitial fibrosis, particularly in juxtamedullary nephrons (tempol vs." | 3.80 | Superoxide dismutase mimetic, tempol, aggravates renal injury in advanced-stage stroke-prone spontaneously hypertensive rats. ( Kohagura, K; Nakamura, T; Ohya, Y; Shinzato, T; Sugama, I; Yamazato, M, 2014) |
| "Candesartan reduced CTGF expression and attenuated the fibrosis in diabetic rat atria." | 3.77 | Angiotensin II type 1 receptor blocker attenuates diabetes-induced atrial structural remodeling. ( Aizawa, T; Fu, LT; Kaneko, S; Kato, T; Sagara, K; Sekiguchi, A; Takamura, M; Tsuneda, T; Yamashita, T, 2011) |
| "To examine the additive protective effects of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone (Pio) and the angiotensin II receptor blocker candesartan (Cand) in a murine model of renal fibrosis: mice with unilateral ureteral obstruction (UUO)." | 3.76 | Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice. ( Higashi, K; Hyodo, T; Kumagai, H; Kushiyama, T; Miura, S; Oda, T; Sakurai, Y; Suzuki, S; Yamada, M, 2010) |
| "After diabetes was initiated, candesartan treatment could not reverse the state of diabetes, but it effectively improved glucose tolerance and protected beta-cell function by attenuating oxidative stress, islet fibrosis, sparsity of blood supply and ultrastructure disruption in a dose-dependent and blood pressure-independent manner." | 3.74 | Angiotensin II receptor blocker provides pancreatic beta-cell protection independent of blood pressure lowering in diabetic db/db mice. ( Du, H; Iwashita, N; Kawamori, R; Shao, JQ; Wang, J; Wang, YT; Wang, YY; Watada, H; Zhao, M, 2007) |
| "Rabbits subjected to ventricular tachypacing at 380 to 400 bpm for 4 weeks in the absence and presence of treatment with pioglitazone, candesartan, and combined pioglitazone and candesartan were assessed by electrophysiologic study, atrial fibrosis measurements, and cytokine expression analyses." | 3.74 | Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. ( Harata, S; Inden, Y; Kitamura, K; Murohara, T; Nattel, S; Shimano, M; Tsuji, Y; Uchikawa, T, 2008) |
| "We recently demonstrated that both lisinopril and candesartan, an angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor blocker, respectively, attenuate pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori (WBN/Kob) rats." | 3.73 | Combination therapy with an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker synergistically suppresses chronic pancreatitis in rats. ( Ando, T; Itoh, M; Joh, T; Kuno, A; Masuda, K; Nakamura, S; Nomura, T; Ogawa, K; Ohara, H; Okamoto, T; Shirai, T; Tang, M; Yamada, T, 2005) |
| "The effect of long-term administration of delapril, an angiotensin converting enzyme inhibitor, and candesartan, an angiotensin II receptor blocker, on cardiac hypertrophy was investigated in spontaneously hypertensive rats (SHR)." | 3.72 | Effect of an ACE inhibitor and an AT1 receptor antagonist on cardiac hypertrophy. ( Shikata, C; Takeda, A; Takeda, N, 2003) |
| "The goal of this study was to determine whether an Angiotensin II receptor antagonist, candesartan, prevents myocardial fibrosis more effectively than enalapril in animals with a non-ACE pathway during the progression of congestive heart failure (CHF)." | 3.72 | Candesartan prevents myocardial fibrosis during progression of congestive heart failure. ( Dohi, K; Funabiki, K; Imanaka-Yoshida, K; Ito, M; Kitamura, T; Koji, T; Nakano, T; Nobori, T; Onishi, K, 2004) |
| "The possible role of calcineurin in the attenuation of cardiac hypertrophy and fibrosis by blockade of the angiotensin II type 1 (AT1) receptor was investigated in Dahl salt-sensitive (DS) rats." | 3.71 | AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats. ( Ichihara, S; Iwase, M; Izawa, H; Nagasaka, T; Nagata, K; Nakashima, N; Obata, K; Odashima, M; Somura, F; Yamada, Y; Yokota, M, 2002) |
| "Fibrosis is characterized by excessive deposition of extracellular matrix components such as collagen in tissues or organs." | 2.66 | Targeting the renin-angiotensin-aldosterone system in fibrosis. ( AlQudah, M; Czubryt, MP; Hale, TM, 2020) |
| "Candesartan treatment also increased the amount of fecal short-chain fatty acids (SCFAs) including acetic acid, propionic acid, and butyric acid in SHRs." | 1.51 | Candesartan attenuates hypertension-associated pathophysiological alterations in the gut. ( Chen, Y; Cui, J; Ding, L; Du, X; Tang, X; Wang, P; Wang, W; Wu, D; Yin, J; Zhang, T, 2019) |
| "Cardiac fibrosis is an important causative mechanism of HF associated with diabetes." | 1.42 | CXCR4 Antagonism Attenuates the Development of Diabetic Cardiac Fibrosis. ( Byrne, M; Chu, PY; Horlock, D; Jandeleit-Dahm, K; Kaye, DM; Nelson, E; Walder, K; Williams, D; Zimmet, P, 2015) |
| "Candesartan treatment for 4 weeks significantly reduced these parameters." | 1.39 | Carbonyl stress induces hypertension and cardio-renal vascular injury in Dahl salt-sensitive rats. ( Chen, X; Endo, S; Guo, Q; Hu, C; Ito, S; Jiang, Y; Miyata, T; Mori, T; Nakayama, K; Nakayama, M; Ogawa, S; Ohsaki, Y; Yoneki, Y; Zhu, W, 2013) |
| "Candesartan was associated with maintenance of XBP-1 expression and attenuated ATF4, cATF6 and CHOP protein expression." | 1.37 | Endoplasmic reticulum stress implicated in the development of renal fibrosis. ( Chang, YW; Cheng, HT; Chiang, CK; Hsu, SP; Huang, JW; Hung, KY; Liu, SH; Wu, CT; Wu, KD, 2011) |
| "Obstruction-induced fibrosis is a leading cause of end-stage renal failure in children." | 1.34 | AT1 receptor blockade prevents interstitial and glomerular apoptosis but not fibrosis in pigs with neonatal induced partial unilateral ureteral obstruction. ( Eskild-Jensen, A; Frøkiaer, J; Nyengaard, JR; Olesen, P; Paulsen, LF; Pedersen, L; Wogensen, L, 2007) |
| " Chronic administration of a subdepressor dose of an angiotensin II type 1 receptor blocker candesartan reduced the pressure overload-induced dihydroethidium and 4-HNE signals at day 3." | 1.33 | Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II. ( Fukui, D; Imaizumi, T; Kai, H; Kudo, H; Kuwahara, F; Mori, T; Sugi, Y; Tahara, N; Takayama, N; Takemiya, K; Tokuda, K; Yasukawa, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 27 (67.50) | 29.6817 |
| 2010's | 10 (25.00) | 24.3611 |
| 2020's | 3 (7.50) | 2.80 |
| Authors | Studies |
|---|---|
| Garg, M | 1 |
| Royce, SG | 1 |
| Tikellis, C | 1 |
| Shallue, C | 1 |
| Batu, D | 1 |
| Velkoska, E | 1 |
| Burrell, LM | 1 |
| Patel, SK | 1 |
| Beswick, L | 1 |
| Jackson, A | 1 |
| Britto, K | 1 |
| Lukies, M | 1 |
| Sluka, P | 1 |
| Wardan, H | 1 |
| Hirokawa, Y | 1 |
| Tan, CW | 1 |
| Faux, M | 1 |
| Burgess, AW | 1 |
| Hosking, P | 1 |
| Monagle, S | 1 |
| Thomas, M | 1 |
| Gibson, PR | 1 |
| Lubel, J | 1 |
| AlQudah, M | 1 |
| Hale, TM | 1 |
| Czubryt, MP | 1 |
| Chen, CM | 1 |
| Chung, YP | 1 |
| Liu, CH | 1 |
| Huang, KT | 1 |
| Guan, SS | 1 |
| Chiang, CK | 2 |
| Wu, CT | 2 |
| Liu, SH | 2 |
| Wu, D | 1 |
| Tang, X | 1 |
| Ding, L | 1 |
| Cui, J | 1 |
| Wang, P | 1 |
| Du, X | 1 |
| Yin, J | 1 |
| Wang, W | 1 |
| Chen, Y | 1 |
| Zhang, T | 1 |
| Sugama, I | 1 |
| Kohagura, K | 1 |
| Yamazato, M | 2 |
| Nakamura, T | 2 |
| Shinzato, T | 2 |
| Ohya, Y | 2 |
| Okazaki, M | 1 |
| Fushida, S | 1 |
| Harada, S | 1 |
| Tsukada, T | 1 |
| Kinoshita, J | 1 |
| Oyama, K | 1 |
| Tajima, H | 1 |
| Ninomiya, I | 1 |
| Fujimura, T | 1 |
| Ohta, T | 1 |
| Chu, PY | 1 |
| Walder, K | 1 |
| Horlock, D | 1 |
| Williams, D | 1 |
| Nelson, E | 1 |
| Byrne, M | 1 |
| Jandeleit-Dahm, K | 1 |
| Zimmet, P | 1 |
| Kaye, DM | 1 |
| Wang, Y | 1 |
| Huang, J | 1 |
| Liu, X | 1 |
| Niu, Y | 1 |
| Zhao, L | 1 |
| Yu, Y | 1 |
| Zhou, L | 1 |
| Lu, L | 1 |
| Yu, C | 1 |
| Ciulla, MM | 1 |
| Paliotti, R | 1 |
| Esposito, A | 1 |
| Cuspidi, C | 1 |
| Muiesan, ML | 1 |
| Rosei, EA | 1 |
| Magrini, F | 1 |
| Zanchetti, A | 1 |
| Meng, G | 1 |
| Wu, F | 1 |
| Yang, L | 1 |
| Zhu, H | 1 |
| Gu, J | 1 |
| He, M | 1 |
| Xu, J | 1 |
| Higashi, K | 1 |
| Oda, T | 2 |
| Kushiyama, T | 1 |
| Hyodo, T | 1 |
| Yamada, M | 2 |
| Suzuki, S | 1 |
| Sakurai, Y | 2 |
| Miura, S | 2 |
| Kumagai, H | 1 |
| Kato, T | 1 |
| Yamashita, T | 1 |
| Sekiguchi, A | 1 |
| Tsuneda, T | 1 |
| Sagara, K | 1 |
| Takamura, M | 1 |
| Kaneko, S | 1 |
| Aizawa, T | 1 |
| Fu, LT | 1 |
| Hsu, SP | 1 |
| Huang, JW | 1 |
| Cheng, HT | 1 |
| Chang, YW | 1 |
| Hung, KY | 1 |
| Wu, KD | 1 |
| Geirsson, A | 1 |
| Singh, M | 1 |
| Ali, R | 1 |
| Abbas, H | 1 |
| Li, W | 1 |
| Sanchez, JA | 1 |
| Hashim, S | 1 |
| Tellides, G | 1 |
| Chen, X | 1 |
| Mori, T | 2 |
| Guo, Q | 1 |
| Hu, C | 1 |
| Ohsaki, Y | 1 |
| Yoneki, Y | 1 |
| Zhu, W | 1 |
| Jiang, Y | 1 |
| Endo, S | 1 |
| Nakayama, K | 1 |
| Ogawa, S | 1 |
| Nakayama, M | 1 |
| Miyata, T | 1 |
| Ito, S | 1 |
| Nagata, K | 1 |
| Somura, F | 1 |
| Obata, K | 1 |
| Odashima, M | 1 |
| Izawa, H | 1 |
| Ichihara, S | 1 |
| Nagasaka, T | 1 |
| Iwase, M | 1 |
| Yamada, Y | 1 |
| Nakashima, N | 1 |
| Yokota, M | 1 |
| Nakatani, T | 1 |
| Tamada, S | 1 |
| Asai, T | 1 |
| Iwai, Y | 1 |
| Kim, T | 1 |
| Tsujino, T | 1 |
| Kumata, N | 1 |
| Uchida, J | 1 |
| Tashiro, K | 1 |
| Kuwabara, N | 1 |
| Komiya, T | 1 |
| Sumi, T | 1 |
| Okamura, M | 1 |
| Miura, K | 1 |
| Shikata, C | 1 |
| Takeda, A | 1 |
| Takeda, N | 1 |
| Yamada, T | 2 |
| Kuno, A | 2 |
| Masuda, K | 2 |
| Ogawa, K | 2 |
| Sogawa, M | 1 |
| Nakamura, S | 2 |
| Ando, T | 2 |
| Sano, H | 1 |
| Nakazawa, T | 1 |
| Ohara, H | 2 |
| Nomura, T | 2 |
| Joh, T | 2 |
| Itoh, M | 2 |
| Tokuda, K | 2 |
| Kai, H | 2 |
| Kuwahara, F | 2 |
| Yasukawa, H | 2 |
| Tahara, N | 2 |
| Kudo, H | 2 |
| Takemiya, K | 2 |
| Koga, M | 1 |
| Yamamoto, T | 1 |
| Imaizumi, T | 2 |
| Mizukami, M | 1 |
| Hasegawa, H | 1 |
| Kohro, T | 1 |
| Toko, H | 1 |
| Kudoh, S | 1 |
| Zou, Y | 1 |
| Aburatani, H | 1 |
| Komuro, I | 1 |
| Tanabe, A | 1 |
| Naruse, M | 1 |
| Hara, Y | 1 |
| Sato, A | 1 |
| Tsuchiya, K | 1 |
| Nishikawa, T | 1 |
| Imaki, T | 1 |
| Takano, K | 1 |
| Gross, O | 1 |
| Schulze-Lohoff, E | 1 |
| Koepke, ML | 1 |
| Beirowski, B | 1 |
| Addicks, K | 1 |
| Bloch, W | 1 |
| Smyth, N | 1 |
| Weber, M | 1 |
| Onishi, K | 1 |
| Dohi, K | 1 |
| Koji, T | 1 |
| Funabiki, K | 1 |
| Kitamura, T | 1 |
| Imanaka-Yoshida, K | 1 |
| Ito, M | 1 |
| Nobori, T | 1 |
| Nakano, T | 1 |
| de Boer, RA | 2 |
| Pokharel, S | 1 |
| Flesch, M | 1 |
| van Kampen, DA | 1 |
| Suurmeijer, AJ | 1 |
| Boomsma, F | 1 |
| van Gilst, WH | 1 |
| van Veldhuisen, DJ | 1 |
| Pinto, YM | 1 |
| Debelle, FD | 1 |
| Nortier, JL | 1 |
| Husson, CP | 1 |
| De Prez, EG | 1 |
| Vienne, AR | 1 |
| Rombaut, K | 1 |
| Salmon, IJ | 1 |
| Deschodt-Lanckman, MM | 1 |
| Vanherweghem, JL | 1 |
| Tang, M | 1 |
| Okamoto, T | 1 |
| Shirai, T | 1 |
| Wake, R | 1 |
| Kim-Mitsuyama, S | 1 |
| Izumi, Y | 1 |
| Yoshida, K | 1 |
| Izumiya, Y | 1 |
| Yukimura, T | 1 |
| Shiota, M | 1 |
| Yoshiyama, M | 1 |
| Yoshikawa, J | 1 |
| Iwao, H | 1 |
| Ko, SH | 1 |
| Hong, OK | 1 |
| Kim, JW | 1 |
| Ahn, YB | 1 |
| Song, KH | 1 |
| Cha, BY | 1 |
| Son, HY | 1 |
| Kim, MJ | 1 |
| Jeong, IK | 1 |
| Yoon, KH | 1 |
| de Borst, MH | 1 |
| van Timmeren, MM | 1 |
| Vaidya, VS | 1 |
| van Dalen, MB | 1 |
| Kramer, AB | 1 |
| Schuurs, TA | 1 |
| Bonventre, JV | 1 |
| Navis, G | 1 |
| van Goor, H | 1 |
| Shao, JQ | 1 |
| Iwashita, N | 1 |
| Du, H | 1 |
| Wang, YT | 1 |
| Wang, YY | 1 |
| Zhao, M | 1 |
| Wang, J | 1 |
| Watada, H | 1 |
| Kawamori, R | 1 |
| Takayama, N | 1 |
| Sugi, Y | 1 |
| Fukui, D | 1 |
| Eskild-Jensen, A | 1 |
| Paulsen, LF | 1 |
| Wogensen, L | 1 |
| Olesen, P | 1 |
| Pedersen, L | 1 |
| Frøkiaer, J | 1 |
| Nyengaard, JR | 1 |
| Omasu, F | 1 |
| Yoshizawa, N | 1 |
| Yamakami, K | 1 |
| Takeda, Y | 1 |
| Zhu, A | 1 |
| Yoneda, T | 1 |
| Usukura, M | 1 |
| Takata, H | 1 |
| Yamagishi, M | 1 |
| Chrysostomakis, SI | 1 |
| Karalis, IK | 1 |
| Simantirakis, EN | 1 |
| Koutsopoulos, AV | 1 |
| Mavrakis, HE | 1 |
| Chlouverakis, GI | 1 |
| Vardas, PE | 1 |
| Shimano, M | 1 |
| Tsuji, Y | 1 |
| Inden, Y | 1 |
| Kitamura, K | 1 |
| Uchikawa, T | 1 |
| Harata, S | 1 |
| Nattel, S | 1 |
| Murohara, T | 1 |
| Wilson, LD | 1 |
| Tsai, CT | 1 |
| Nakamoto, M | 1 |
| Mano, R | 1 |
| Sakima, A | 1 |
| Takishita, S | 1 |
| Ikeda, Y | 1 |
| Takano, H | 1 |
| Kimura, H | 1 |
| Obata, JE | 1 |
| Takeda, S | 1 |
| Hata, A | 1 |
| Shido, K | 1 |
| Mochizuki, S | 1 |
| Yoshida, Y | 1 |
1 review available for candesartan and Cirrhosis
| Article | Year |
|---|---|
Targeting the renin-angiotensin-aldosterone system in fibrosis.
Topics: Amides; Angiotensins; Animals; Benzimidazoles; Biphenyl Compounds; Extracellular Matrix; Extracellul | 2020 |
1 trial available for candesartan and Cirrhosis
| Article | Year |
|---|---|
Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angiotensin-co
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benz | 2009 |
38 other studies available for candesartan and Cirrhosis
| Article | Year |
|---|---|
Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Cell Proliferat | 2020 |
Withaferin A protects against endoplasmic reticulum stress-associated apoptosis, inflammation, and fibrosis in the kidney of a mouse model of unilateral ureteral obstruction.
Topics: Animals; Apoptosis; Benzimidazoles; Biphenyl Compounds; Disease Models, Animal; Endoplasmic Reticulu | 2020 |
Candesartan attenuates hypertension-associated pathophysiological alterations in the gut.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Colon; Fatty Acids; Feces; Fibrosis; Ga | 2019 |
Superoxide dismutase mimetic, tempol, aggravates renal injury in advanced-stage stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antioxidants; Benzimidazo | 2014 |
The angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Agents; Benzimidazoles; Biphenyl Co | 2014 |
CXCR4 Antagonism Attenuates the Development of Diabetic Cardiac Fibrosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzylamines; Biphenyl Compounds; | 2015 |
β-Arrestin-biased AT1R stimulation promotes extracellular matrix synthesis in renal fibrosis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; beta-Arrestin 1; b | 2017 |
Synergistic attenuation of myocardial fibrosis in spontaneously hypertensive rats by joint treatment with benazepril and candesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazep | 2009 |
Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biomarkers; Biphenyl | 2010 |
Angiotensin II type 1 receptor blocker attenuates diabetes-induced atrial structural remodeling.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Benzimidazoles; Biphenyl Com | 2011 |
Endoplasmic reticulum stress implicated in the development of renal fibrosis.
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Apoptosis; Benzimidazoles; Biphenyl Compounds; Blo | 2011 |
Modulation of transforming growth factor-β signaling and extracellular matrix production in myxomatous mitral valves by angiotensin II receptor blockers.
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compounds; Cells, Cultured; Co | 2012 |
Carbonyl stress induces hypertension and cardio-renal vascular injury in Dahl salt-sensitive rats.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; B | 2013 |
AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood | 2002 |
Role of renin-angiotensin system and nuclear factor-kappaB in the obstructed kidney of rats with unilateral ureteral obstruction.
Topics: Angiotensin Receptor Antagonists; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Fibrosi | 2002 |
Effect of an ACE inhibitor and an AT1 receptor antagonist on cardiac hypertrophy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimid | 2003 |
Candesartan, an angiotensin II receptor antagonist, suppresses pancreatic inflammation and fibrosis in rats.
Topics: Actins; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2003 |
Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Benzimidazoles; Biphenyl Co | 2004 |
Gene expression profile revealed different effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibitor on heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; B | 2003 |
Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats.
Topics: Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; B | 2004 |
Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimid | 2004 |
Candesartan prevents myocardial fibrosis during progression of congestive heart failure.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Disease Progression; Dogs; Fibrosis; Heart Failure; Mal | 2004 |
Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Atr | 2004 |
The renin-angiotensin system blockade does not prevent renal interstitial fibrosis induced by aristolochic acids.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aristolo | 2004 |
Combination therapy with an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker synergistically suppresses chronic pancreatitis in rats.
Topics: Actins; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazol | 2005 |
Beneficial effect of candesartan on rat diastolic heart failure.
Topics: Aldehydes; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Benzimidazoles; Biphenyl Com | 2005 |
High glucose increases extracellular matrix production in pancreatic stellate cells by activating the renin-angiotensin system.
Topics: Angiotensin I; Angiotensin II; Animals; Benzimidazoles; Biphenyl Compounds; Collagen; Connective Tis | 2006 |
Induction of kidney injury molecule-1 in homozygous Ren2 rats is attenuated by blockade of the renin-angiotensin system or p38 MAP kinase.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Atrial | 2007 |
Angiotensin II receptor blocker provides pancreatic beta-cell protection independent of blood pressure lowering in diabetic db/db mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2007 |
Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2006 |
AT1 receptor blockade prevents interstitial and glomerular apoptosis but not fibrosis in pigs with neonatal induced partial unilateral ureteral obstruction.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Apoptosis; Benzi | 2007 |
Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Disease Models | 2007 |
Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensinog | 2007 |
Angiotensin II type 1 receptor inhibition is associated with reduced tachyarrhythmia-induced ventricular interstitial fibrosis in a goat atrial fibrillation model.
Topics: Animals; Atrial Fibrillation; Benzimidazoles; Biphenyl Compounds; Cardiac Pacing, Artificial; Diseas | 2007 |
Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Benzimi | 2008 |
Heart failure-related atrial fibrillation: a new model for a new prevention strategy?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Benzimidazoles; Biphenyl Comp | 2008 |
Pioglitazone, a thiazolidinedione derivative, attenuates left ventricular hypertrophy and fibrosis in salt-sensitive hypertension.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Fibrosis; Hypertension; Hypertrophy, Lef | 2008 |
Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2000 |